Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31890| Title: | Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. | Austin Authors: | Margalit, Ofer;Harmsen, William S;Shacham-Shmueli, Einat;Voss, Molly M;Boursi, Ben;Wagner, Anna D;Cohen, Romain;Olswold, Curtis L;Saltz, Leonard B;Goldstein, Daniel A;Hurwitz, Herbert;Tebbutt, Niall C ;Kabbinavar, Fairooz F;Adams, Richard A;Chibaudel, Benoist;Grothey, Axel;Yoshino, Takayuki;Zalcberg, John;de Gramont, Aimery;Shi, Qian;Lenz, Heinz-Josef | Affiliation: | Austin Health Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel. University of Melbourne, Australia Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA. Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel. Department of Quantitative Science Research, Mayo Clinic, Scottsdale, AZ, USA. Department of Oncology, Division of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Memorial Sloan Kettering Cancer Centre, New York, NY, USA. Rabin Medical Centre, Petach Tikvah, Israel. Duke Cancer Institute, Duke University, Durham, NC, USA. David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA. Cardiff University and Velindre Cancer Centre, Cardiff, UK. Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France. West Cancer Center, Germantown, TN, USA. Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan. Department of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia. Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France. Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA. Department of Gastrointestinal Oncology, Keck School of Medicine at USC, Los Angeles, CA, USA. |
Issue Date: | Jan-2023 | Date: | 2022 | Publication information: | European Journal of Cancer 2023; 178 | Abstract: | Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31890 | DOI: | 10.1016/j.ejca.2022.10.022 | ORCID: | Journal: | European Journal of Cancer (Oxford, England : 1990) | Start page: | 162 | End page: | 170 | PubMed URL: | 36446161 | ISSN: | 1879-0852 | Type: | Journal Article | Subjects: | ARCAD Age Bevacizumab Colorectal carcinoma Metastatic Sex Bevacizumab/therapeutic use Colorectal Neoplasms/drug therapy |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.